Trial Profile
An Open-Label Extension Study to Evaluate the Long-Term Effects of ACE-536 in Patients With β-Thalassemia Previously Enrolled in Study A536-04
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 24 May 2023
Price :
$35
*
At a glance
- Drugs Luspatercept (Primary)
- Indications Beta-thalassaemia
- Focus Adverse reactions
- Sponsors Acceleron Pharma
- 17 Jun 2021 Results presented at the 26th Congress of the European Haematology Association
- 17 Jun 2021 Results analyzing MCV variation as an early predictor of response to Luspatercept by using data from phase II/III clinical trials (NCT01749540, NCT02268409, NCT02604433, NCT03342404, NCT04064060) presented at the 26th Congress of the European Haematology Association
- 13 Jul 2020 Status changed from active, no longer recruiting to completed.